Chugai Pharmaceutica (CHGCF) 29.3500 $CHGCF
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.81 (unch), NBS: 2.98 (+0.06), OSIR: 17.56 (+0.84), BCLI: 4.63 (+0.31), MDVN: 132.44 (+0.38), INO: 9.78 (-0.18), CYTX: 1.24 (-0.02), STEM: 1.00 (-0.01), JUNO: 60.39 (+1.15), ATHX: 3.03 (+0.03), CUR: 1.94 (+0.07), BLUE: 126.34 (+1.49), VRTX: 128.47 (+2.83), AMGN: 163.38 (+1.89), KERX: 12.42 (+0.09), OMER: 24.58 (+0.44), KITE: 58.34 (+0.22), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), TEVA: 66.37 (-0.77)
Will Stem Cell Profits Measure Up?: NxR Biotechnologies' Alain Vertès
Life Sciences Report - Seeking Alpha - Thu Mar 19, 6:10AM CDT
It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative...
PFE: 35.44 (+0.41), ATHX: 3.03 (+0.03)
Chugai licenses ISPRI/OptiMatrix platform from EpiVax for de-risking biologics
PR Newswire - Thu Oct 30, 10:17AM CDT
Chugai Pharmaceutical Co., Ltd. (Chugai), signed an agreement with Rhode Island-based biotechnology company, EpiVax, Inc., to incorporate EpiVax's ISPRI immunogenicity screening and deimmunization technology into Chugai's drug development toolbox. Chugai is widely regarded as one of the most cutting edge biopharmaceutical companies in Japan. Researchers at Chugai will be utilizing the cloud-based in silico "Interactive Protein Screening and Reengineering Interface" (ISPRI) in conjunction with OptiMatrix, a tool for deimmunizing biologics, to screen and re-engineer therapeutic proteins for potential immunogenicity and deimmunize immune-dominant epitopes, known as clusters.
Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report
M2 - Thu Aug 14, 2:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqzzts/growth_factors) has announced the addition of the "Growth Factors (Blood and Tissue) - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins) - Tissue Growth Factors. The report profiles 90 companies including many key and niche players such as: - Alseres Pharmaceuticals, Inc. - Amgen, Inc. - Bayer HealthCare Pharmaceuticals, Inc. - Biogen Idec Inc - BioMimetic Therapeutics, Inc. - Biopharm GmbH - Bolder Biotechnology, Inc. - F. Hoffmann-La Roche Ltd - Chugai Pharmaceutical Co. Ltd. - Genentech, Inc. - FibroGen, Inc. - Johnson & Johnson - Janssen Biotech, Inc. - Lonza Group - Merck Serono International S.A. - NsGene A/S - PeproTech, Inc. - Reliance GeneMedix Plc - Sangamo BioSciences, Inc. - Sanofi - Shantha Biotechnics - Scil Proteins GmbH - Wockhardt Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Growth Factors An Overview 3. Research Studies & Clinical Trials 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 90 (including Divisions/Subsidiaries 95) - The United States (42) - Japan (
- Europe (19) - France (1) - Germany ( - The United Kingdom (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (24) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/bq...th_factors
JNJ: 102.06 (+0.73), BIIB: 425.65 (-0.98), MRK: 57.25 (-0.18), SGMO: 15.41 (+0.29), AMGN: 163.38 (+1.89)
Helsinn Group and Chugai Pharma Marketing Enter Into Agreement for Marketing Rights of Netupitant-Palonosetron Fixed-Dose Combination (NEPA) in the UK and Ireland and for Palonosetron Monotherapy in the UK
PR Newswire - Thu Jul 17, 1:00AM CDT
Under the exclusive agreement, Chugai Pharma Marketing gains rights for the marketing of palonosetron in the UK and NEPA in the UK and in Ireland from Helsinn Group, strengthening the existing alliance between the companies in therapeutic area of supportive cancer care.
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.81 (unch), NBS: 2.98 (+0.06), OSIR: 17.56 (+0.84), BCLI: 4.63 (+0.31), MDVN: 132.44 (+0.38), INO: 9.78 (-0.18), CYTX: 1.24 (-0.02), STEM: 1.00 (-0.01), JUNO: 60.39 (+1.15), ATHX: 3.03 (+0.03), CUR: 1.94 (+0.07), BLUE: 126.34 (+1.49), VRTX: 128.47 (+2.83), AMGN: 163.38 (+1.89), KERX: 12.42 (+0.09), OMER: 24.58 (+0.44), KITE: 58.34 (+0.22), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), TEVA: 66.37 (-0.77)
Will Stem Cell Profits Measure Up?: NxR Biotechnologies' Alain Vertès
Life Sciences Report - Seeking Alpha - Thu Mar 19, 6:10AM CDT
It makes no sense to look at stem cell companies differently from drug or biologics companies. The technology may be different, but the diseases they seek to treat are the same. In fact, cell therapies may ultimately be more useful and more curative...
PFE: 35.44 (+0.41), ATHX: 3.03 (+0.03)
Chugai licenses ISPRI/OptiMatrix platform from EpiVax for de-risking biologics
PR Newswire - Thu Oct 30, 10:17AM CDT
Chugai Pharmaceutical Co., Ltd. (Chugai), signed an agreement with Rhode Island-based biotechnology company, EpiVax, Inc., to incorporate EpiVax's ISPRI immunogenicity screening and deimmunization technology into Chugai's drug development toolbox. Chugai is widely regarded as one of the most cutting edge biopharmaceutical companies in Japan. Researchers at Chugai will be utilizing the cloud-based in silico "Interactive Protein Screening and Reengineering Interface" (ISPRI) in conjunction with OptiMatrix, a tool for deimmunizing biologics, to screen and re-engineer therapeutic proteins for potential immunogenicity and deimmunize immune-dominant epitopes, known as clusters.
Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report
M2 - Thu Aug 14, 2:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqzzts/growth_factors) has announced the addition of the "Growth Factors (Blood and Tissue) - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins) - Tissue Growth Factors. The report profiles 90 companies including many key and niche players such as: - Alseres Pharmaceuticals, Inc. - Amgen, Inc. - Bayer HealthCare Pharmaceuticals, Inc. - Biogen Idec Inc - BioMimetic Therapeutics, Inc. - Biopharm GmbH - Bolder Biotechnology, Inc. - F. Hoffmann-La Roche Ltd - Chugai Pharmaceutical Co. Ltd. - Genentech, Inc. - FibroGen, Inc. - Johnson & Johnson - Janssen Biotech, Inc. - Lonza Group - Merck Serono International S.A. - NsGene A/S - PeproTech, Inc. - Reliance GeneMedix Plc - Sangamo BioSciences, Inc. - Sanofi - Shantha Biotechnics - Scil Proteins GmbH - Wockhardt Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Growth Factors An Overview 3. Research Studies & Clinical Trials 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 90 (including Divisions/Subsidiaries 95) - The United States (42) - Japan (
- Europe (19) - France (1) - Germany ( - The United Kingdom (1) - Rest of Europe (9) - Asia-Pacific (Excluding Japan) (24) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/bq...th_factors JNJ: 102.06 (+0.73), BIIB: 425.65 (-0.98), MRK: 57.25 (-0.18), SGMO: 15.41 (+0.29), AMGN: 163.38 (+1.89)
Helsinn Group and Chugai Pharma Marketing Enter Into Agreement for Marketing Rights of Netupitant-Palonosetron Fixed-Dose Combination (NEPA) in the UK and Ireland and for Palonosetron Monotherapy in the UK
PR Newswire - Thu Jul 17, 1:00AM CDT
Under the exclusive agreement, Chugai Pharma Marketing gains rights for the marketing of palonosetron in the UK and NEPA in the UK and in Ireland from Helsinn Group, strengthening the existing alliance between the companies in therapeutic area of supportive cancer care.
